Results 151 to 160 of about 104,869 (316)

When Treatment Meets Natural History: Understanding Early Dermatitis‐Related Adverse Events in Systemic Atopic Dermatitis Trials

open access: yesJEADV Clinical Practice, EarlyView.
ABSTRACT Biologics and Janus kinase (JAK) inhibitors have transformed the management of atopic dermatitis (AD), yet some patients experience early worsening of disease activity during treatment initiation. In clinical trials, these events are typically recorded as treatment‐emergent adverse events (TEAEs), most commonly coded as “atopic dermatitis”. We
Diego Ruiz Dasilva   +17 more
wiley   +1 more source

Vulvar pruritus [PDF]

open access: yesBMJ Case Reports, 2020
Catarina Estevinho   +3 more
openaire   +2 more sources

A Practical Guide for Incorporating Emollients in the Treatment of Mild‐to‐Moderate Atopic Dermatitis

open access: yesJEADV Clinical Practice, EarlyView.
ABSTRACT Emollients and cleansers are essential components in managing atopic dermatitis (AD). While international evidence‐based guidelines recommend using gentle cleansers and emollients daily as a foundational therapy for AD, implementation in practice remains suboptimal.
Mette Deleuran   +12 more
wiley   +1 more source

Chronic Kidney Disease‐Associated Pruritus Is Linked to Selective Enrichment of Taurine‐Conjugated Bile Acid Subspecies

open access: yesJEADV Clinical Practice, EarlyView.
Chronic kidney disease‐associated pruritus (CKDaP) is a frequent complication of advanced CKD with an incompletely understood pathophysiology. We identified a significantly altered glycine‐to‐taurine conjugated bile acid ratio in patients with CKDaP despite unchanged total serum bile acid concentrations.
Miriam M. Düll   +6 more
wiley   +1 more source

Serum Eosinophil Level Correlates With Atopic Dermatitis Severity: A Multicenter Cross‐Sectional Study in Chinese Patients With a Nested Cohort Analysis of Dupilumab Treatment Response

open access: yesJEADV Clinical Practice, EarlyView.
ABSTRACT Background Personalized treatment strategies for atopic dermatitis (AD) are limited. Although serum total IgE (tIgE) and blood eosinophil levels are proposed biomarkers for AD severity, their clinical utility requires validation. Objectives We aimed to identify biomarkers reflecting AD severity and their association with dupilumab efficacy ...
Zhuying Zhang, Jingwen Xue, Yi Zhao
wiley   +1 more source

Position statement : linear prurigo is a subtype of chronic prurigo

open access: yes, 2019
: Background Chronic prurigo (CPG) is a distinct disease characterized by chronic pruritus, history and/or signs of prolonged scratching and multiple pruriginous lesions.
Misery, L.   +34 more
core  

Real‐World Effectiveness and Safety of Topical Ruxolitinib in Adolescents With Vitiligo: A 52‐Week Retrospective Study

open access: yesJEADV Clinical Practice, EarlyView.
Topical ruxolitinib 1.5% cream was assessed in 39 adolescents with non‐segmental vitiligo. Median T‐VASI fell at week 24 (n = 34) and week 52 (n = 18), with repigmentation most pronounced on the face: 55.6% reached F‐VASI50 at week 52. Few adverse events were recorded, all mild application‐site reactions in 4 of 39 patients.
L. Coronella   +3 more
wiley   +1 more source

Chronic Pruritic Papular Eruption in an Elderly Man

open access: yes
JEADV Clinical Practice, EarlyView.
Filipe Monteiro   +6 more
wiley   +1 more source

Subcorneal Pustular Dermatosis, a Systematic Review and Pooled Analysis of a Rare and Underdiagnosed Disease

open access: yesJEADV Clinical Practice, EarlyView.
ABSTRACT Background Subcorneal pustular dermatosis (SPD), or Sneddon–Wilkinson disease, is a rare, relapsing pustular skin condition of unknown cause, characterised by subcorneal pustules. Objectives To summarise the demographic, clinical, histopathological, management and disease course of SPD.
Mason H. Crossman   +5 more
wiley   +1 more source

Home - About - Disclaimer - Privacy